November 14th, 2026Kidney Compass: Platform Trials in IgA Nephropathy and Glomerular DiseaseSuceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.Read more
November 15th, 2026Kidney Compass: FIND-CKD Finerenone Data in FSGS and Treatment SequencingHiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.Read more
November 15th, 2026Kidney Compass: GFR Slope and Hierarchical Composite Endpoints in Glomerular DiseaseLesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.Read more
November 14th, 2026FDA Approves Obinutuzumab (Gazyva) for Primary Membranous NephropathyApproval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.Read more
November 19th, 2026ABCs in Dermatology: Evolving Therapies and Dermatology's Role in Cutaneous Lupus CareAckerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.Read more
November 19th, 2026Q&A: Interpreting Pediatric Nemolizumab Data for AD, With Lawrence Eichenfield, MDLawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.Read more
November 18th, 2026What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next. Read more
November 18th, 2026Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics. Read more